Quick Answer
Karyopharm Therapeutics Inc. reported Research And Development Expense of $125.62 million for the year ending 2025.
- Karyopharm Therapeutics Inc. showed a decrease of -12.3% in Research And Development Expense from 2024 to 2025.
- This data is from Karyopharm Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on February 13, 2026.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 15 years of available data (2011 to 2025), Karyopharm Therapeutics Inc.'s Research And Development Expense has grown by 1,356.8%.
- Historical annual values: Fiscal year 2025: $125.62 million | Fiscal year 2024: $143.23 million | Fiscal year 2023: $138.75 million | Fiscal year 2022: $148.66 million | Fiscal year 2021: $160.84 million | Fiscal year 2020: $150.81 million | Fiscal year 2019: $122.34 million | Fiscal year 2018: $161.37 million | Fiscal year 2017: $107.27 million | Fiscal year 2016: $86.94 million | Fiscal year 2015: $97.74 million | Fiscal year 2014: $60.13 million | Fiscal year 2013: $28.45 million | Fiscal year 2012: $14.10 million | Fiscal year 2011: $8.62 million.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: